有投资者向复星医药提问, 请问下复星管理层,截止2024年三季度,公司暂停研发的管线有哪些,合计研发成本是多少?暂停研发的管线,是否视为研发失败?有哪些研发项目确认为研发失败?研发失败的管线是否计提资产减值准备?公司回答表示,投资者您好!在创新研发推进过程中,公司持续动态评估管线的市场价值,并结合临床策略和研发资源配置等综合因素,对相关管线的研发推进、优先级进行适时调整,故暂停研发的管线并不一定...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.